Abstract
Daptomycin is a lipopeptide bactericidal antimicrobial indicated in the treatment of skin and soft tissue infections (SSTI), Staphylococcus aureus-related right-sided infective endocarditis (RIE) and bacteremia secondary to these infections. The recommended dosage in patients with previous renal impairment is 4 mg/kg/48 hours in SSTI. There are no data published for SSTI and RIE followed by bacteremia. Based on pharmacokinetic models, the recommended dosage in patients under hemodialysis is 4 mg/kg after dialysis. The present article aims to review of the latest published data on daptomycin use in patients with renal impairment and to relate these findings to preliminary data from the EUCORE registry in Spain.
Copyright © 2010 Elsevier España S.L. All rights reserved.
MeSH terms
-
Aged
-
Aminoglycosides / adverse effects
-
Aminoglycosides / toxicity
-
Animals
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / adverse effects*
-
Anti-Bacterial Agents / pharmacokinetics
-
Anti-Bacterial Agents / therapeutic use
-
Bacteremia / complications
-
Bacteremia / drug therapy
-
Daptomycin / administration & dosage
-
Daptomycin / adverse effects*
-
Daptomycin / pharmacokinetics
-
Daptomycin / therapeutic use
-
Databases, Factual / statistics & numerical data
-
Endocarditis, Bacterial / complications
-
Endocarditis, Bacterial / drug therapy
-
Gram-Positive Bacterial Infections / drug therapy*
-
Humans
-
Kidney / drug effects
-
Kidney / metabolism
-
Kidney Failure, Chronic / complications*
-
Kidney Failure, Chronic / therapy
-
Metabolic Clearance Rate
-
Multicenter Studies as Topic / statistics & numerical data
-
Muscular Diseases / chemically induced
-
Peritoneal Dialysis
-
Registries / statistics & numerical data
-
Renal Dialysis
-
Retrospective Studies
-
Soft Tissue Infections / complications
-
Soft Tissue Infections / drug therapy
-
Staphylococcal Infections / drug therapy
Substances
-
Aminoglycosides
-
Anti-Bacterial Agents
-
Daptomycin